|
Year
|
Drug/site
|
N
|
PD3
|
Excluded/lost
|
LCF
|
LPF
|
ACPR
|
Kaplan–Meier
|
|---|
|
n (%)
|
n (%)
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
|---|
|
2011
|
ASAQ
|
|
Ujiji
|
73
|
0
|
8 (11.0)
|
13.8 (6.5–24.7)
|
10.8 (4.4–20.9)
|
75.4 (63.1–85.2)
|
76.1 (64.0–84.6)
|
|
Kibaha
|
29
|
0
|
4 (13.8)
|
0 (0.0–13.7)
|
0 (0.0–13.7)
|
100 (86.3–100)
|
100
|
|
AL
|
|
Muheza
|
32
|
2 (6.3)
|
2 (6.3)
|
0 (0.0–11.6)
|
3.3 (0.1–17.2)
|
96.7 (82.8–99.9)
|
96.9 (79.8–99.6)
|
|
2012
|
AL
|
|
Chamwino
|
26
|
0
|
3 (11.5)
|
0 (0.0–14.8)
|
4.3 (0.1–21.9)
|
95.7 (78.1–99.9)
|
95.7 (72.9–99.4)
|
|
Kyela
|
44
|
0
|
8 (18.2)
|
5.6 (0.7–18.7)
|
16.7 (6.4–32.8)
|
77.8 (60.8–89.9)
|
78.9 (62.3–88.9)
|
|
Nagaga
|
62
|
0
|
23 (37.1)
|
0 (0.0–9.0)
|
0 (0.0–9.0)
|
100 (91.0–100)
|
100
|
|
2015
|
AL
|
|
Kyela
|
80
|
0
|
16 (20.0)
|
4.7 (1.0–13.1)
|
1.6 (0.0–8.4)
|
93.8 (84.8–98.3)
|
94.1 (85.0–97.8)
|
|
DHA-PQ
|
|
Rufiji
|
82
|
0
|
10 (12.2)
|
1.4 (0.0–7.5)
|
0 (0.0–5.0)
|
98.6 (92.5–100)
|
98.6 (90.8–99.8)
|
- PD3 positive on day 3, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate + amodiaquine, AL artemether + lumefantrine, DHAPQ dihydroartemisinin + piperaquine
